Healthcare >> Analyst Interviews >> November 6, 2000

European Pharmaceuticals Stocks

STEWART ADKINS is a graduate of Biochemistry and Genetics from Leeds University. After spending two years at Ford Motor Company as a Product Planning Analyst in the Truck Division he joined Lilly as a detail man. Were it not for the demise of Opren he might have been there today. However, after two years he joined Lehman Brothers' predecessor and trained as a Pharmaceutical Analyst. He has worked in the City for over 17 years and has worked with Healthcare Team members, Jo Walton and Ian Smith for most of that time. Well known amongst investors (rated in Top three by Institutional Investor) and pharmaceutical companies alike, their regular publication Pharmabulletin and ad hoc research, PharmaPipelines and Valuation publications have achieved wide circulation. Mr Adkins is married with two children. Profile
TWST: Could we start with a synopsis of the key sector developments over

the past six months; what have been the issues?

Mr. Adkins: I think the key sector developments actually have taken